{"title":"Approaching a therapeutic inflection point for FLT3-mutated AML.","authors":"Alexander E Perl","doi":"10.1182/blood.2024024248","DOIUrl":null,"url":null,"abstract":"<p><strong>Abstract: </strong>Combining FMS-like tyrosine kinase 3 (FLT3) inhibitors with intensive chemotherapy and transplant has substantially improved acute myeloid leukemia (AML) outcomes, prompting a recent reevaluation of the historically negative prognostic effect of FLT3 internal tandem duplication. Treatment approaches may soon undergo major changes because emerging data suggest maximal intensity does not benefit all patients and measurable residual disease potentially can guide several treatment choices. Finally, recent data also suggest that FLT3 inhibitors could transform outcomes in patients unsuitable for intensive therapy. If confirmed, this has important implications for fit patients and could revolutionize the treatment paradigm.</p>","PeriodicalId":9102,"journal":{"name":"Blood","volume":" ","pages":"2834-2839"},"PeriodicalIF":23.1000,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Blood","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1182/blood.2024024248","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Abstract: Combining FMS-like tyrosine kinase 3 (FLT3) inhibitors with intensive chemotherapy and transplant has substantially improved acute myeloid leukemia (AML) outcomes, prompting a recent reevaluation of the historically negative prognostic effect of FLT3 internal tandem duplication. Treatment approaches may soon undergo major changes because emerging data suggest maximal intensity does not benefit all patients and measurable residual disease potentially can guide several treatment choices. Finally, recent data also suggest that FLT3 inhibitors could transform outcomes in patients unsuitable for intensive therapy. If confirmed, this has important implications for fit patients and could revolutionize the treatment paradigm.
期刊介绍：
Blood, the official journal of the American Society of Hematology, published online and in print, provides an international forum for the publication of original articles describing basic laboratory, translational, and clinical investigations in hematology. Primary research articles will be published under the following scientific categories: Clinical Trials and Observations; Gene Therapy; Hematopoiesis and Stem Cells; Immunobiology and Immunotherapy scope; Myeloid Neoplasia; Lymphoid Neoplasia; Phagocytes, Granulocytes and Myelopoiesis; Platelets and Thrombopoiesis; Red Cells, Iron and Erythropoiesis; Thrombosis and Hemostasis; Transfusion Medicine; Transplantation; and Vascular Biology. Papers can be listed under more than one category as appropriate.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
